Biogen Inc. stock rises 1.50% to $183.38, outperforming market competitors

11 articles · Updated · MarketWatch · Apr 28

On Tuesday, Biogen Inc. shares ended a three-day losing streak, closing at $183.38 with a 1.50% gain despite the S&P 500 and Dow Jones both declining.
Trading volume reached 1.2 million, surpassing the 50-day average, while Biogen outperformed Johnson & Johnson, Pfizer, and AbbVie during a broadly negative market session.
The stock remains 9.40% below its 52-week high of $202.41 set on February 6, highlighting ongoing volatility in the sector.

Is Biogen stock truly 54% undervalued, or is market skepticism about its turnaround justified?

How will global drug pricing pressures impact the profitability of Biogen's new therapies?

Can Biogen's billion-dollar acquisitions truly offset the decline of its core business?

As Biogen deepens ties in China, what geopolitical risks could disrupt its growth strategy?

Which of Biogen's 10 late-stage trials holds the ultimate key to its long-term success?

Will Alzheimer's drug Leqembi deliver on its promise as Biogen's next-generation blockbuster?